

**EFFECTS OF SOME DRUGS ON FREE RADICAL PROCESSES IN THE GASTRIC
MUCOSA IN A MODEL OF GASTROPATHY IN RATS**

^{1,2}Djanaev G.Yu., ^{1,2}Mustanov T.B., ^{1,2}Mamadjanova M.A., ¹Kakhkharova SH.B.

Tashkent Medical Academy, Department of Pharmacology, Tashkent, Uzbekistan

Alfraganus University, Tashkent, Uzbekistan

Abstract: In gastropathy developed under the influence of indomethacin in the gastric mucosa, the effect of some pharmacological agents on the amount of acylhydroperoxides and malondialdehyde and the activity of catalase and superoxide dismutase enzymes was studied. All of the used drugs have been found to have a similar effect on the peroxidation of fats and the activity of enzymes of the antioxidant system. Lesboxol, a combination of plant extracts, has been proven to be more active than Mucogen (rebamipid) and Misoprostol.

Key words: Gastropathy, indomethacin, fat peroxidation, antioxidant system, gastroprotector.

Introduction. One of the urgent problems of practical medicine is gastropathies that develop when using anti-inflammatory drugs [1,2,8,19]. The reason for this is that non-steroidal anti-inflammatory drugs (NSAIDs) are widely used not only as anti-inflammatory, anti-aggregant, but also as antipyretic and pain relievers [3,4,11,20]. However, in these cases, almost all patients have gastric disorders [5,11,14]. Taking into account that the effectiveness of preventive measures and tools used in gastropathies is low, the creation of new drugs is one of the important tasks of pharmacology [5,7,16]. Free radical oxidation - the development of oxidative stress has been found to be one of the main links in the pathogenesis of many pathologies, including gastropathies [6,7,8,9,10]. The formed free radicals damage the subcellular structures and biological membranes of cells. As a result, dysfunction of organs and systems is observed [9,17,18]. Therefore, it is necessary to use substances with antioxidant properties to prevent gastropathy. In this regard, the new compound Lesboxol, which has gastroprotective properties in models of gastropathy induced by stress, ethanol, reserpine and indomethacin, was of particular interest. Lesboxol is a complex drug consisting of dry extracts of 4 types of plants - Hypericum scabrum, Ziziphora pedicellata, Elder grass (*Medicago macrophylla*), common licorice (*Glycyrrhiza glabra*) [1,3]. Although Lesboxol reduces the development of gastropathy under the influence of pathogenic factors, its cytoprotective properties have not been fully studied.

Purpose of work. Comparative study of the effect of Lesboxol, Misoprostol and Mucogen on the process of peroxidation of fats in the gastric mucosa and the activity of enzymes of the antioxidant system in gastropathies developed under the influence of Indomethacin.

Materials and Methods.

Experimental studies were conducted on male rats with an initial weight of 165-185 g. Five groups of six animals each were formed. One day and 2 hours before the induction of the gastropathy model, the animals of the first, second and third groups were injected intragastrically with the following doses: Misoprostol - 0.2 mg/kg, Lesboxol - 50 mg/kg, Mucogen (rebamipid) - 100 mg/kg. The fourth group of rats was given the appropriate amount of water (control), and the fifth group consisted of healthy animals, which served as a control for the rest (healthy). In

animals of the first, second, third and fourth groups, nonsteroidal anti-inflammatory drug (NSAQV) - indomethacin 60 mg/kg in physiological solution was administered intragastrically to create a model of gastropathy [10,13]. Rats were deprived of food for 24 hours before creating a model of indomethacin-induced gastropathy.

24 hours after the introduction of drugs, the activity of lipid peroxidation products (LPO) and antioxidant system (AOT) enzymes was determined.

For biochemical studies, animals were slaughtered under light ether anesthesia in a cold room at a temperature of $0 \pm 4^{\circ} \text{C}$. After the gastric mucosa was separated, the weight was determined and washed with cold physiological solution. A homogenate was prepared in a 3-4 times volume of 15 TB/ml contrical and 3 TB/ml heparin solution in a glass container with a Teflon pestle. Homogenates were centrifuged at 9,000 g for 30 min to pellet nuclei, mitochondria, and cellular debris. It is known that the increase in LPO processes in the cell membrane and subcellular structures leads to the degradation of membrane phospholipids, which, in turn, disrupts intracellular homeostasis and slows down complex metabolic and synthetic processes in the cell. The main powerful defense mechanism in the cell that prevents LPO activity is the antioxidant system. The vital activity of the cell directly depends on the level of activity of factors that enhance lipid peroxidation and the activity of AOT enzymes [5,19]. Considering the above, in order to evaluate the state of lipid peroxidation, we measured the amount of lipid peroxidation products [acyl hydroperoxide (AtsGP), malondialdehyde (MDA)] and AOT [catalase (KT), superoxide dismutase (SOD)] enzymes in the supernatant fraction of the gastric mucosa homogenate. activity was determined. AtsGP was determined by the method of V.B. Gavrillov and others [9]. The method is based on separation of lipid hydroperoxide with a heptane-isopropanol mixture in an acidic environment, and then measuring the optical density with a spectrophotometer at a wavelength of 233 nm. The amount of AtsGP was expressed in relative units relative to mg of protein. MDA was determined by the method of L.I. Andreeva [7]. Products reacting with thiobarbituric acid were calculated using a molar extinction coefficient of MDA of $1.56 \times 10^5 \text{ mol cm}$ and calculated per mg of protein. QD activity was determined by the method of M.A. Korolyuk [12]. The method is based on the ability of H_2O_2 to form a stable color with molybdenum salts. The staining intensity was measured in a spectrophotometer at a wavelength of 410 nm. The obtained data are expressed in mmol $\text{H}_2\text{O}_2/\text{min.mg}$ of protein. SOD activity was determined by the percent reduction of nitrotetrazol blue in alkaline medium and expressed in conditional units per mg of protein [15,16]. The results of the studies were subjected to statistical processing using the Biostat 2009 software package, the significance of $M \pm m$ characteristics and the differences in the considered samples according to the Student's test were evaluated according to the statistical method. Differences between the compared groups were considered at the 95% ($P < 0.05$) confidence level.

Results and its discussion.

The results of biochemical studies showed that the amount of AtsGP increased by 89.0%, MDA increased by 71.7%, CT activity decreased by 36.8%, and SOD decreased by 62.7% in the gastric mucosa of control animals compared to healthy animals. observed. Therefore, the damage of indomethacin to the gastric mucosa (MShQ) is based on the development of oxidative stress, which was manifested in an increase in the level of lipid peroxidation products and a decrease in the activity of protective enzymes of AOT.

In our experiment, it was observed that the changes in the group of animals that received gastroprotective agents for the purpose of prevention were different. AtsGP and MDA

concentrations in the gastric mucosa under the influence of misoprostol were reduced by 12.6% and 2.0% compared to the control, but it was not statistically significant. As shown in Table 1, these data were 16.4 and 12.5%, respectively, in mucogen-treated animals, and 28.2 and 27.3%, respectively, in lesbokhol-treated animals.

It can be said that the studied gastroprotectors reduce the intensity of free radical oxidation (ERO), which may be the result of an increase in the activity of the antiradical system. Indeed, CT and SOD activity increased by 6.4 and 61.7%, and mucogen by 25.8 and 68.3%, respectively, in misoprostol-treated animals. We found higher changes in studied parameters in animals treated with lesboxhol, where CT activity was 45.1% higher and SOD was 140.0% higher compared to the control group.

The effect of misoprostol, mucogen and lesbokhol on the intensity of free radical lipid oxidation and the activity of antioxidant system enzymes in gastric mucosa in indomethacin-induced gastropathy (M±m, n=6).

Indicators Groups	AtsGP (indicated, units per mg of protein)	MDA (nmol per mg protein)	CT (mmol H2O2 min. per mg protein)	SOD (TB per mg protein)
Healthy	0,197±0,010	0,177±0,012	0,049±0,002	0,161±0,012
Control	0,372±0,019*	0,304±0,026*	0,031±0,002*	0,060±0,003*
Misoprostol Ndomethacin	+0,325±0,024*	0,298±0,015*	0,033±0,003*	0,097±0,007*
Mucogen indomethacin	+0,311±0,023*	0,266±0,017*	0,039±0,003	0,101±0,008*.#
Lesboxol Indomethacin	+0,267±0,018*.#	0,221±0,020 [#]	0,045±0,003 [#]	0,144±0,010 [#]

Note: * - statistically significant difference compared to healthy animals, # - statistically significant difference compared to control animals (P<0.05).

Apparently, lesbokhol is superior not only to misoprostol, but also to mucogen in terms of pharmacological activity. In general, the presented results of biochemical studies show that the increase in ERO as a result of the reduction of AOT is the main pathogenetic factor in the development of destructive-erosive damage of the gastric mucosa in indomethacin-induced gastropathy. Drugs studied in the treatment of gastropathy prevent the development of ERO and have a beneficial effect on the components of the immune system of the gastric mucosa. In this regard, lesbokhol is relatively superior to the effectiveness of other drugs. This situation can be the basis for its use as an effective tool in stomach pathology.

The conclusion.

1. One of the important causes of gastropathies developed under the influence of indomethacin is an increase in the process of peroxidation of fats due to a sharp decrease in the activity of enzymes of the antioxidant system.
2. Synthetic analogue of prostaglandin E1 - Misoprostol shows a weak antioxidant effect in gastropathy developed under the influence of indomethacin.
3. Prostaglandin E2 production-stimulating drug Mucogen is based on the cytoprotective effect of a statistically reliable reduction of peroxide oxidation of fats in the gastric mucosa and an increase in the activity of the antioxidant system.

4. In terms of its pharmacological activity, "Lesboxol", a combination of plant extracts, is superior to Mucogen and especially Misoprostol in gastric injury caused by indomethacin.

REFERENCES USED

1. Allaeva, M. Z., Dzhanayev, G. Y., Khudoiberdiev, K. И., Mamadzhanova, M. A., & Mustanov, T. B. (2020). Influence of lesboxol dry extract on the current of experimental nervo-reflective gastric ultra. *European Journal of Molecular and Clinical Medicine*, 7(3), 2749-2753.
2. Djanayev G'. Yu., Allaeva M. J., Xolmatov J. A. Immobilizatsion stress yo'li bilan chaqirilgan me'da yarasida o'simliklar quruq ekstrakti yig'masining samaradorligini o'rganish : dis. – "O'zbekistonda Milliy Tadqiqotlar: Davriy Anjumanlar:", 2022.
3. Djanayev G. et al. Immobilizatsiya stressi fonida oq kalamushlarda me'da shilliq qavatining shikastlanishiga" lesboxol" o'simlik vositasining ta'siri : dis. – Tibbiyotning dolzarb muammolariga innovatsion yondashuv C. 20- 22, 2022.
4. Kamada T. et al. Yevidence-based clinical practice guidelines for peptic ulcer disease 2020 //Journal of gastroenterology. – 2021. – T. 56. – №. 4. – S. 303-322.
5. Khakimov Z. Z. Yeffect of Derivatives of Glycyrrhetic Acid on the Intensity of Free Radical Processes During Immobilization Stress //Pioneer: Journal of Advanced Research and Scientific Progress. – 2022. – T. 1. – №. 1. – S. 7-12.
6. Omastu T. et al. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury //Journal of gastroenterology. – 2010. – T. 45. – №. 7. – S. 692-702.]
7. Андреева Л.И., Кожемякин Л.А., Кишкун А.А. Модификация метода определения перекисей липидов в тесте с тиобарбитуровой кислотой.//Лабораторное дело.- 1988.- №11.- С.41-43.
8. Балуква Е. В. НПВП-индуцированная гастропатия: от понимания механизмов развития к разработке стратегии профилактики и лечения //РМЖ. – 2017. – Т. 25. – №. 10. – С. 697-702.